AbbVie, Inc. (ABBV)

84.34
NYSE
Prev Close 84.31
Day Low/High 83.94 / 85.15
52 Wk Low/High 62.55 / 101.28
Exchange NYSE
Shares Outstanding 1764.83B
Market Cap 148.79B
P/E Ratio 72.63
Div & Yield N.A. (N.A)
Immatics Is a Bit Boy Who Cried Wolf

Immatics Is a Bit Boy Who Cried Wolf

This is the type of chart that will grab the attention of momentum traders.

This Dividend Stock's Got the Right Medicine for Investors

This Dividend Stock's Got the Right Medicine for Investors

AbbVie stock is a rare combination of value, growth, and yield, making it a unique pick in the health care sector.

Weakening Dollar, Fiscal Relief Gridlock, Walmart+, Trading Albemarle

Weakening Dollar, Fiscal Relief Gridlock, Walmart+, Trading Albemarle

Also, interpreting Tuesday's market, Covid-19 vaccine update, and manufacturing growth.

A Healthy Dose of Vaccine and Pharmaceutical Plays

A Healthy Dose of Vaccine and Pharmaceutical Plays

6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.

Stay Patient With AbbVie

Stay Patient With AbbVie

I would continue to hold ABBV, and here's why.

2 Biotech Stocks to Buy on Solid Q2 Results

2 Biotech Stocks to Buy on Solid Q2 Results

Covid-19 has had a big impact on this sector, but these names have strong catalysts going into the next quarter.

Let's Not Overlook AbbVie's Q2 Beat

Let's Not Overlook AbbVie's Q2 Beat

There is no thought of selling here and now, even with politicized pressure on the industry.

Grotesque GDP, So Much for Rotation, Amazon Goes Wild: Market Recon

Grotesque GDP, So Much for Rotation, Amazon Goes Wild: Market Recon

Plus, it could be quite a while before the labor market can absorb all those people who are out of jobs.

7 Drug Stocks With the Right Medicine for Investors

7 Drug Stocks With the Right Medicine for Investors

These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities

I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.

AbbVie Is Concocting a Formula for a Breakout

AbbVie Is Concocting a Formula for a Breakout

Here's an updated strategy for ABBV, which could see new highs soon.

The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance

I have always liked the aggressive management.

The Charts of AbbVie Can Reach New Heights

The Charts of AbbVie Can Reach New Heights

A lifting on the moratorium on elective procedures could be a big win for ABBV.

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession

What's really driving the market, what's making the Nasdaq roar? Tech and science, that's what.

Markets Test Support Levels, Amazon Earnings, Calibrating for Covid-19

Markets Test Support Levels, Amazon Earnings, Calibrating for Covid-19

The market sold off on Thursday after close as big hitters, including Amazon, reported earnings.

Jim Cramer: I Don't Think Covid-19 Is Invincible

Jim Cramer: I Don't Think Covid-19 Is Invincible

When it's beaten you will wish you own stocks, especially the stocks that are right now lethal to your portfolio.

A New Technical Strategy for AbbVie

A New Technical Strategy for AbbVie

Let's check out the charts of ABBV.

Jim Cramer: Finding Any Stocks With No Hair?

Jim Cramer: Finding Any Stocks With No Hair?

After a company reports we all know what's wrong, it's immunized. And that's when you can buy.

This Health Care Dividend King Offers a Remedy for Hopeless Investors

This Health Care Dividend King Offers a Remedy for Hopeless Investors

JNJ should survive a recession and prove in demand in a health crisis.

These Are the Times We Live In

These Are the Times We Live In

Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.

Jim Cramer: Panicking Never Made Anyone a Dime, but These Will

Jim Cramer: Panicking Never Made Anyone a Dime, but These Will

Here are six companies that should come through in the tough times ahead.

Jim Cramer: Let's See Who's Safe, Who Isn't

Jim Cramer: Let's See Who's Safe, Who Isn't

You can use these wild market swings to your advantage by identifying 'safe' companies you want to own and then buying their stocks in stages.

Jim Cramer: Rate Cut No Cure for Coronavirus

Jim Cramer: Rate Cut No Cure for Coronavirus

But don't throw up your arms yet -- here are names that could be golden opportunities.

Jim Cramer: I Don't Know Where It Will Bottom, I Do Know What to Buy and Sell

Jim Cramer: I Don't Know Where It Will Bottom, I Do Know What to Buy and Sell

This is the time to high grade your portfolio, take some losses and move to better stocks.

AbbVie Could Be One of the Stocks That Recovers Before Others

AbbVie Could Be One of the Stocks That Recovers Before Others

Let's review the charts and indicators.

Three Strategies for Income Investors

Three Strategies for Income Investors

For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.

Coronavirus Spreads, Reducing 'Big Oil', 4 Stocks to Watch, Adding Store Capital

Coronavirus Spreads, Reducing 'Big Oil', 4 Stocks to Watch, Adding Store Capital

Newly confirmed cases of the Covid-19 virus spiked from Hubei Province in China, where the city of Wuhan is located. The number of related deaths increased as well.

Tech Based Rally, Real-Life Virus, Powell Speaks, Tracking 5 Stocks

Tech Based Rally, Real-Life Virus, Powell Speaks, Tracking 5 Stocks

This rally has been industry, not sector led, and it is all based on technology, whether or not market leaders reside within the Tech sector or not.

Watch These Biotech Names on Strong Earnings

Watch These Biotech Names on Strong Earnings

Merger activity is the number 1 driver I am watching for biotech growth.